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Abstract
Background: Preconditioning is a phenomenon by which tolerance develops to injury by previous exposure to a
stressor of mild severity. Previous studies have shown that single or repeated low dose MDMA can attenuate 5-HT
transporter loss produced by a subsequent neurotoxic dose of the drug. We have explored the mechanism of
delayed preconditioning by low dose MDMA.
Methods: Male Dark Agouti rats were given low dose MDMA (3 mg/kg, i.p.) 96 h before receiving neurotoxic
MDMA (12.5 mg/kg, i.p.). IL-1b and IL1ra levels and 5-HT transporter density in frontal cortex were quantified at 1
h, 3 h or 7 days. IL-1b, IL-1ra and IL-1RI were determined between 3 h and 96 h after low dose MDMA. sIL-1RI
combined with low dose MDMA or IL-1b were given 96 h before neurotoxic MDMA and toxicity assessed 7 days
later.
Results: Pretreatment with low dose MDMA attenuated both the 5-HT transporter loss and elevated IL-1b levels
induced by neurotoxic MDMA while producing an increase in IL-1ra levels. Low dose MDMA produced an increase
in IL-1b at 3 h and in IL-1ra at 96 h. sIL-1RI expression was also increased after low dose MDMA. Coadministration
of sIL-1RI (3 μg, i.c.v.) prevented the protection against neurotoxic MDMA provided by low dose MDMA.
Furthermore, IL-1b (2.5 pg, intracortical) given 96 h before neurotoxic MDMA protected against the 5-HT
neurotoxicity produced by the drug, thus mimicking preconditioning.
Conclusions: These results suggest that IL-1b plays an important role in the development of delayed
preconditioning by low dose MDMA.
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Background
3,4- Methylenedioxymethamphetamine (MDMA or
“ecstasy”), an amphetamine derivative, is a popular drug
of abuse among young people. In experimental animals,
MDMA produces a series of immediate neurochemical,
biochemical and behavioural effects as well as producing
long-term species-specific neurotoxicity [1]. In rats,
MDMA produces an apparent loss of 5-HT nerve term-
inals [2,3] demonstrated by immunohistochemical tech-
niques and biochemically the damage is reflected by a
substantial decrease in the concentration of 5-HT and
its metabolite, 5-hydroxyindolacetic acid (5-HIAA) [4,5]
and a reduction in the density of 5-HT uptake sites
labelled with [
3H]-paroxetine [4,6,7]. MDMA produces a
hyperthermic response immediately after injection
which lasts at least 5-6 h and appears to modulate the
long-term neuronal damaged caused by the drug [8,9].
MDMA also produces a neuroinflammatory response
characterised by an increase in mature IL-1b and of its
precursor protein (pro-IL-1b) in rat frontal cortex as
well as microglial activation [9,10].
When exposed to practically any stimulus capable of
causing injury at a level close to (but below) the thresh-
old of damage, most living organisms respond with pro-
tective mechanisms to potentially recurring challenges.
Janoff introduced the term “preconditioning” for this
phenomenon [11]. The preconditioning phenomenon
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ing the brain, and in different models of injury. Pre-
exposure to heat shock treatment, mild ischemia or
hypoxia induces tolerance against a subsequent neuro-
toxic insult in rodents [12-16]. The development of pre-
conditioning may involve a number of different effectors
including the activation of cellular defence mechanisms
such as antioxidant systems, heat shock proteins and
cell death/survival determinants, or responses at tissue
level for example reduced inflammatory responsiveness
[17]. In line with this ischemic tolerance has been
shown to involve IL-1b and IL-1ra [12,18,19]. Repeated
exposure to heat shock offers protection against
MDMA-induced 5-HT neurotoxicity in Dark Agouti
rats [13] and more recently it has been established that
prior exposure of adult rats to MDMA provides protec-
tion against a subsequent MDMA-induced 5-HT deple-
tion in the brain [20,21]. The neuroprotection exerted is
independent of the ambient temperature at which the
low dose MDMA is given [21] and does not appear to
involve the hyperthermic response, alterations in brain
MDMA pharmacokinetics or changes in 5-HT transpor-
ter activity [20, 21, unpublished observations].
IL-1b is often described as the prototypical pro-
inflammatory cytokine. Released in response to local or
systemic injury or disease, IL-1b orchestrates host
defence response. It is a potent pyrogen [22] and a key
mediator of innate and adaptive immune response [23].
IL-1b exerts its action by binding of IL-1 type I receptor
(IL-1RI), forming a complex which then binds to the IL-
1R accessory protein (IL-1RAcP), resulting in the initia-
tion of signal transduction [24]. IL-1 receptor antagonist
(IL-1ra) is a competitive antagonist of IL-1RI that selec-
tively binds, but fails to trigger receptor association with
the accessory protein resulting in the blockade of all
known actions of IL-1. The extracellular domain of IL-
1RI may also be proteolytically cleaved from the cell
surface giving rise to IL-1 soluble type I receptor (IL-
1sRI) [25]. This soluble form of the receptor binds both
IL-1b and IL-1ra but does not initiate signal
transduction.
The aims of this study were: 1) to describe MDMA
preconditioning (interval, number of doses), 2) to exam-
ine the time-course of low dose MDMA-induced
changes in IL-1b, IL-1ra levels and soluble and mem-
brane bound IL-1RI expression in rat frontal cortex, 3)
to study the effect of exogenously administered sIL-1RI
on the protection induced by MDMA pre-treatment
against subsequent neurotoxic MDMA, and 4) to ana-
lyse the effect of exogenously administered IL-1b against
subsequent neurotoxic MDMA.
We have demonstrated that low dose MDMA can
provide long-lasting neuroprotection against a subse-
quent challenge of higher dose MDMA and that the
preconditioning appears to involve low dose MDMA-
induced IL-1b release.
Methods
Animals, drugs and reagents
Male Dark Agouti rats (175-200 g, Harlan Labora-
tories Models, Barcelona) were used. MDMA induces
a reproducible acute hyperthermic response in this
strain [5,26] and also a reproducible long-term neuro-
toxic loss of 5-HT terminals after a single dose [5].
Rats were housed in groups of 5 in conditions of con-
stant temperature (21°C ± 2°C) and a 12 h light/dark
cycle (lights on: 08 h 00 min) and given free access to
food and water. Low dose MDMA (3 mg/kg, i.p.) was
given once or repeatedly (1 injection daily for 4 days)
to rats and 24 h, 96 h or 7 days later animals received
neurotoxic MDMA (12.5 mg/kg, i.p.). Room tempera-
ture at the time of MDMA administration was 21-22°
C. To determine neurotoxicity, [
3H]-paroxetine-
labelled 5-HT transporter density was measured in
frontal cortex 7 days after neurotoxic MDMA. To
determine IL-1b and IL-1ra levels and IL-1RI expres-
sion, animals were killed 3 h, 6 h, 24 h or 96 h after
MDMA (3 mg/kg, i.p.) or 1 h or 3 h after receiving
neurotoxic MDMA.
MDMA hydrochloride (LIPOMED, Arlesheim, Suiza)
was dissolved in saline (0.9% NaCl) and given in a
volume of 1 mL/kg. The dose is reported in terms of
the base. Control animals were injected with saline.
For intracerebroventricular (i.c.v.) and intracortical
administrations rats were anesthetized with a mixture of
isoflurane (3.5% for induction, 1-2% for maintenance;
flow rate 1.5 L min
-1) and nitrous oxide/oxygen mixture
(30/70%) in air and placed in a stereotaxic frame
secured in a Kopf stereotaxic frame with the tooth bar
3.3 mm below interaural zero. A 22 G guide cannula
was implanted in the right lateral ventricle or frontal
cortex (according to the following coordinates: for ven-
tricle: 7.9 mm rostral to the interaural line, 0.8 mm lat-
eral to the midline and 3.1 mm below the skull surface;
and for cortex: 8.9 mm rostral to the interaural line, 0.4
mm lateral to the midline and 2.1 mm below the skull
surface [27]. The cannula was secured to the skull as
described by Baldwin et al. [28]. Injections took place 5
days after surgery through a 28 G injector (Plastics One,
Roanoke, VA, USA) which fitted in and protruded 1
mm beyond the guide cannula.
Soluble interleukin-1 receptor type I (sIL-1RI; Sigma-
Aldrich, Madrid, Spain) and recombinant rat IL-1b
(R&D Systems, Minneapolis, MN, USA) were dissolved
in phosphate-buffered saline (PBS) containing 0.1%
bovine serum albumin (BSA). sIL-1RI (3 μgi n5μLo f
PBS over 5 min; i.c.v.) was administered 5 min before
and 3 h after low dose MDMA. IL-1b (2.5 pg in 5 μL
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neurotoxic MDMA.
All experimental procedures were performed in accor-
dance with the guidelines of the Animal Welfare Com-
mittee of the Universidad Complutense de Madrid
(following European Council Directives 86/609/CEE and
2003/65/CE).
Measurement of rectal temperature
Immediately before and up to 6 h after MDMA injec-
tion, temperature was measured by use of a digital read-
out thermocouple (BAT12 thermometer, Physitemp, NJ,
USA) with a resolution of 0.1°C and accuracy of ± 0.1°C
attached to a RET-2 Rodent Sensor which was inserted
2.5 cm into the rectum of the rat, the animal being
lightly restrained by holding it in the hand. A steady
readout was obtained within 10 s of probe insertion.
Western blot for IL-1RI immunoreactivity
Expression of IL-1RI was determined in the soluble and
membrane fractions of frontal cortex by Western blot.
Preparation of soluble and membrane fractions was car-
ried out by modification of the method described by
Wang et al. [29]. Tissue was homogenized by sonication
in ice-cold buffer contain 50 mM Tris, 320 mM sucrose
and a number of phosphatase and protease inhibitors
(0.2 M phenylmethanesulphonylfluoride, 0.5 M NaVO4,
1MN a M o O 4 and Complete Mini, Roche, Spain). Sam-
ples were centrifuged at 100 000 × g for 60 min at 4°C
and protein determined in the supernatant [30]. This
was the fraction containing the soluble form of IL-1RI.
The pellet was resuspended in the same buffer by soni-
cation. The homogenate was centrifuged 12 000 × g for
20 min at 4°C and protein determined in the superna-
tant [30]. This was the fraction containing the mem-
brane bound form of IL-1RI.
The samples were boiled in Laemmli buffer and ali-
quots containing 100 μg of protein were separated by
10% SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred to nitrocellulose membranes.
Nonspecific sites were blocked by incubation for 1 h in
TBS containing 5% skimmed milk. Membranes were
incubated overnight at 4°C with monoclonal rabbit anti
IL-1RI (Abcam, UK; 1:1000) as primary antibody fol-
lowed by incubation with anti-rabbit IgG-horseradish
peroxidase (GE Healthcare, Spain; 1:2000) for 2 h. Equal
protein sample loading was confirmed by quantification
of the b-actin signal.
Immunoreactivity was detected with an enhanced che-
miluminescence Western blot detection system (GE
Healthcare) followed by exposure to Amersham Hyper-
film ECL (GE Healthcare) for 1-10 min. Different film
exposure times were used to ensure that band were not
saturated. Quantification of specific bands on the film
was performed using the Quantity One program
(BioRad Laboratories, Inc, CA, USA). Each IL-1RI band
density was normalised for protein content by referring
it to its b-actin band density and then the IL-1RI
expression in the different experimental conditions was
expressed as a percentage of the control group.
IL-1b and IL-1ra immunoassays
Brain levels of IL-1b and IL-1ra were determined in
frontal cortex using commercially available sandwich
enzyme-linked immunosorbent assays (ELISA) (Rat IL-
1b/IL-1F2 and Human IL-1ra/IL-1F3 Quantikine ELISA
Kits, respectively; R&D Systems, Minneapolis, MN,
USA). According to the manufacturer, the IL-1b kit pro-
vides a valid measure of the levels of mature 17 kDa IL-
1b (the limit of sensitivity was 5 pg/mL) but underesti-
mates the precursor form 31 kDa IL-1b (non-biologi-
cally active). Samples were prepared by homogenization
in 5 volumes of ice-cold buffer (50 mM Tris, 320 mM
sucrose, 1 mM dithiothreitol, 10 μg/mL leupeptin, 2 μg/
mL aprotinin and 0.2% phenantroline; pH 7.0). Samples
were centrifuged at 14 000 × g for 20 min at 4°C. Pro-
tein was determined in the supernatant [30]. Samples
were assayed in triplicate following the manufacturer’s
guidelines. Quantification was performed using a stan-
dard curve of increasing concentrations of IL-1b or IL-
1ra. The optical density of each well was determined
using a microplate reader (ELX808 IU, Ultra Microplate
Reader, Bio-Tek Instruments, VT, USA) set to 450 nm
(correction wavelength set at 540 nm). Intra-assay and
inter-assay variations were less than 5% and 15%,
respectively, for both kits.
Quantification of 5-HT transporter density by [
3H]-
paroxetine binding
[
3H]-Paroxetine binding was measured by the method
described in detail by Hewitt and Green [6]. Briefly,
frontal cortex from individual animals was homogenized
in ice-cold Tris-HCl (50 mM; pH 7.4) containing NaCl
(120 mM) and KCl (5 mM) using an Ultra-Turrax. The
homogenate was centrifuged at 30 000 × g for 10 min at
4°C. The supernatant was discarded and the wash proce-
dure repeated twice more. The pellet was finally resus-
pended in the Tris buffer at a concentration of 10 mg
tissue/mL. Aliquots of tissue (800 μL) were incubated
with a saturating concentration of [
3H]-paroxetine (1
nM, specific activity = 21.4 Ci/mmol, Perkin-Elmer,
Spain) for 90 min at room temperature in the absence
and presence of 5-HT (100 μM) for determination of
total and non-specific binding, respectively. Assays were
terminated by rapid filtration through glass fibre filters
and radioactivity determined by scintillation spectrome-
try. Protein was determined by the method of Lowry et
al. [31].
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Data from ELISA, immunoreactivity and 5-HT transpor-
ter studies were analyzed using one-way ANOVA fol-
lowed by Newman-Keuls multiple-comparisons test
when a significant F value was obtained. Statistical ana-
lyses of temperature measurements were performed by
two-way ANOVA with repeated measures using treat-
ment as the between subjects factor and time as the
repeated measure, followed by Bonferroni as post-test
(GraphPad Prism 5; GraphPad Software Inc., San Diego,
CA, USA).
Results
Effect of pretreatment with low dose MDMA against
MDMA-induced loss of 5-HT uptake sites in frontal cortex
To study the effect of pretreatment with low dose
MDMA on the loss of 5-HT uptake sites (5-HTT) pro-
duced by a neurotoxic dose of MDMA, rats were treated
with a daily dose of MDMA (3 mg/kg, i.p.) for 4 conse-
cutive days and given MDMA (12.5 mg/kg, i.p.) 24 h
after the final dose. Separate groups of animals were
given a single MDMA (3 mg/kg, i.p.) injection 24 h, 96
h or 7 days before MDMA (12.5 mg/kg, i.p.)
administration.
Pretreatment with repeated low dose MDMA attenu-
ated the decrease in 5-HTT density induced by a subse-
quent neurotoxic dose of MDMA in the frontal cortex
(58% protection) but did not modify the density of 5-
HT uptakes sites in saline treated-animals (Figure 1A).
Administration of a single low dose MDMA injection 24
h or 96 h before neurotoxic MDMA also prevented the
loss of 5-HTT (Figure 1B). The level of protection was
similar to that observed following repeated doses and
similar for both intervals (71-72%), however, when low
dose MDMA was given 7 days before neurotoxic
MDMA, the protection provided was less marked (42%;
Figure 1B).
Effect of pretreatment with low dose MDMA on
neurotoxic MDMA-induced hyperthermia
Two-way ANOVA indicated that there was a significant
effect of treatment (F3,20 = 104.4, P < 0.0001), time
(F9,180 = 87.0, P < 0.0001) and interaction (F27,180 =
9.48, P < 0.0001). Bonferroni post test revealed that
MDMA (12.5 mg/kg, i.p.) produced a hyperthermic
response which peaked 60 min after treatment and was
sustained for up to 6 h after treatment. Pretreatment
with a single low dose of MDMA (3 mg/kg, i.p.) 96 h
earlier did not affect the hyperthermia of neurotoxic
MDMA or the rectal temperature of saline-treated ani-
mals (Figure 1C).
Since a single low dose of MDMA administered 96 h
before neurotoxic MDMA provided extensive delayed
Figure 1 Effect of pretreament with low dose MDMA (3 mg/kg,
i.p.) on MDMA (12.5 mg/kg, i.p.)-induced neurotoxicity in
frontal cortex 7 days later. (A) Pretreatment with four consecutive
doses of low dose MDMA attenuated the loss of 5-HT transporters
induced by neurotoxic MDMA given 24 h later. (B) Pretreatment
with a single low dose of MDMA attenuated the loss of 5-HT
transporters induced by neurotoxic MDMA given 24 h, 96 h or 168
h (7 days) later. (C) Pretreatment with low dose MDMA 96 h earlier
did not modify neurotoxic MDMA-induced hyperthermia. The arrow
marks the time of neurotoxic MDMA injection. Results shown as
mean ± s.e.mean, n = 5-8. Different from saline-treated controls: *P
< 0.05, **P < 0.001. Different from neurotoxic MDMA:
ΔP < 0.05,
ΔΔP
< 0.01. One-way ANOVA followed by Newman-Keuls test.
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studies.
Effect of pretreatment with low dose MDMA on
neurotoxic MDMA-induced changes in IL-1b and IL-1ra
levels in frontal cortex
Administration of neurotoxic MDMA (12.5 mg/kg, i.p.)
produced an increase in IL-1b levels in frontal cortex 3
h after injection as previously described [9,32]. Pretreat-
ment with a single low dose of MDMA (3 mg/kg, i.p.)
96 h before giving the neurotoxic dose attenuated this
increase in IL-1b (Figure 2A).
Neurotoxic MDMA did not modify IL-1ra levels in
frontal cortex as described previously [33], however pre-
treatment with low dose MDMA produced an increase
in IL-1ra levels 1 h after the neurotoxic dose (Figure
2B).
Effect of low dose MDMA on IL-1b and IL-1ra levels in
frontal cortex
For the examination of IL-1b and IL-1ra levels following
low dose MDMA, animals were killed 3 h, 6 h, 24 h and
96 h after an injection of MDMA 3 mg/kg. Administra-
tion of a single low dose of MDMA produced an
increase in IL-1b levels in the frontal cortex 3 h after
injection compared with the saline-treated control group
(Figure 3A). However, no changes in levels were
observed 6 h, 24 h or 96 h after injection.
A single low dose of MDMA produced an increase in
IL-1ra levels in the frontal cortex 96 h after administra-
tion without producing significant changes in the levels
at earlier time points (Figure 3B).
Effect of low dose MDMA on IL-1 receptor type I (IL-1RI)
expression in frontal cortex
IL-1RI expression in the membrane and soluble frac-
tions of frontal cortex was measured 3 h, 6 h, 24 h and
96 h after low dose MDMA administration.
MDMA did not alter IL-1RI expression in the mem-
brane fraction at any of the time-points examined (Fig-
ure 3C). However, in the soluble fraction a biphasic
response was observed. IL-1RI expression increased 3 h
and 6 h after MDMA, returned to control levels at 24 h
and rose again at 96 h (Figure 3D).
Effect of sIL-1RI on the protection provided by low dose
MDMA against neurotoxic MDMA
MDMA (12.5 mg/kg, i.p.) produced a decrease in the
density of 5-HTT in both ipsi- and contralateral frontal
cortex 7 days after treatment. This 5-HTT loss was atte-
nuated by pretreatment with MDMA (3 mg/kg, i.p.)
given 96 h before the neurotoxic dose (Figure 4A, B).
Injection of sIL-1RI (3 μg per animal, i.c.v.) 5 min before
and 3 h after low dose MDMA prevented the
neuroprotection exerted by the pretreatment in the ipsi-
lateral cortex (Figure 4A) but failed to modify it in the
contralateral side (Figure 4B). sIL-1RI administration
alone did not alter MDMA neurotoxicity in the frontal
Figure 2 Effect of pretreatment with a single low dose of
MDMA (3 mg/kg, i.p.) 96 h before on MDMA (12.5 mg/kg, i.p.)-
induced changes in IL-1b and IL-1ra levels in frontal cortex. (A)
Pretreatment with low dose MDMA attenuated the increase in IL-1b
produced by neurotoxic MDMA 3 h later. (B) Pretreatment with low
dose MDMA produced an increase in IL-1ra levels 1 h after
neurotoxic MDMA. Results shown as mean ± s.e.mean, n = 7-8.
Different from saline-treated controls: *P < 0.05. Different from
neurotoxic MDMA:
ΔP < 0.05,
ΔΔP < 0.01. One-way ANOVA followed
by Newman-Keuls test. Levels of the cytokines in animals treated
only with low dose MDMA were not included but were considered
to be similar to those observed at the 96 h time point of Figure 3.
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soluble (D) fractions of frontal cortex. MDMA produced 1 h later an increase in IL-1b levels (A) and 96 h later an increase in IL-1ra (B). IL-1RI
expression was unaltered in the membrane fraction (C) but increased in the soluble fraction 3 h, 6 h and 96 h after MDMA (D). (E) and (F) are
representative images from the Western blots of membrane (E) and soluble (F) fractions of frontal cortex. Results shown as mean ± s.e.mean, n
= 4-8. Different from saline-treated controls: *P < 0.05, **P < 0.01. Different from neurotoxic MDMA:
ΔP < 0.01,
ΔΔP < 0.001. One-way ANOVA
followed by Newman-Keuls test.
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treated controls (Figure 4A, B). Furthermore, the admin-
istration of sIL-1RI did not alter neurotoxic MDMA-
induced hyperthermia (data not shown).
Effect of pretreatment with IL-1b on the 5-HTT loss
induced by neurotoxic MDMA
In order to avoid any dilution of the effects by the use
of tissue which had not been reached the IL- b injection,
only tissue around the injection site was used in this
assay. Tissue was obtained 2 mm rostral to and caudal
from the injection site using a rat brain matrix.
As described above, MDMA (12.5 mg/kg, i.p.) pro-
duced a significant reduction in the density of 5-HTT in
the ipsi- and contralateral sides of the frontal cortex 7
days later (Figure 5A, B). Injection of IL-1b (2.5 pg,
intracortical) 96 h before administration of neurotoxic
MDMA (12.5 mg/kg, i.p.) attenuated the reduction in
the density of [
3H]-paroxetine-labelled 5-HT uptake
sites (Figure 5A). In the contralateral cortex, IL-1b pre-
treatment did not attenuate the decrease in the density
of 5-HT uptake sites induced by neurotoxic MDMA
(Figure 5B).
Discussion
Preconditioning, a phenomenon by which exposure to a
non-harmful stimulus confers tolerance to subsequent
exposure to a more intense stimulus of the same or of a
different nature, has been described in many different
tissues and organs following exposure to a diverse range
of stimuli [17,34]. We have previously described a
model of “cross-tolerance” in which heat-shock pretreat-
ment protects against the 5-HT neurotoxicity induced
by MDMA [13] and more recently low dose MDMA-
induced tolerance has been described [20,21]. The pre-
sent results indicate an important role for interleukin-
1beta (IL-1b) in the development of this low dose
MDMA-induced tolerance against the 5-HT neurotoxi-
city induced by a higher subsequent dose of the drug.
I nt h ep r e s e n ts t u d yw eo b s e r v e dt h a tt h ep r o t e c t i o n
produced by low dose MDMA is not dependent on the
number of doses applied since a single dose of MDMA
3 mg/kg protects to a similar extent as 4 consecutive
administrations against the toxicity of neurotoxic
MDMA given 24 h later. The protection provided by a
single low dose of MDMA is long-lasting being observed
when the pretreatment is given 24 h and 96 h earlier
and continuing to provide partial protection when given
up to 7 days before the higher dose of MDMA. The
results agree with those of Piper et al [35,36] who
described protection against binge MDMA-induced 5-
HT neurotoxicity 7 days following chronic exposure to
low doses of the drug in both adolescent and adult rats
b u td i f f e rf r o mt h o s ed e s c r i b e db yB h i d eet al [20]
where tolerance against a binge dosing regimen of 10
mg/kg every 2 h for 4 doses was relatively transient in
nature and lost when the window was extended to 4
days. The time-scale of neuroprotection observed indi-
cates that the processes involved in its development
Figure 4 Effect of sIL-1RI given with low dose MDMA (3 mg/kg,
i.p.) on the protection against MDMA (12.5 mg/kg, i.p.)-
induced loss of 5-HT transporters in ipsilateral (A) and
contralateral (B) frontal cortex 7 days later. Neurotoxic MDMA
reduced the number of 5-HT transporters in both sides of the
frontal cortex and this was prevented by low dose MDMA given 96
h earlier. Administration of sIL-1RI (3 μg, i.c.v.) 5 min before and 3 h
after low dose MDMA prevented this protection in ipsilateral but
not in contralateral frontal cortex. Results shown as mean ± s.e.
mean, n = 5-7. Different from saline-treated controls: *P < 0.01, **P
< 0.001. Different from neurotoxic MDMA:
ΔP < 0.05,
ΔΔP < 0.01.
Different from MDMA3/MDMA12.5:
fP < 0.05. One-way ANOVA
followed by Newman-Keuls test.
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provide a wide window for protection. Studies in other
lesion models in which tolerance can be induced by
exposure to a less intense stimulus have revealed two
windows in which tolerance develops. The first is a
rapid tolerance which is observed minutes after the
trigger and lasts for hours involving factors such as
KATP channels, nitric oxide, adenosine and protein
kinase alpha/delta [34]. A second window of protection,
delayed tolerance, develops over hours and days, and
usually involves de novo protein synthesis. Most indu-
cers of tolerance can produce both rapid and delayed
tolerance. The protection observed in this study can be
described as delayed tolerance since it develops hours
after the initial insult [34]. Whether or not low dose
MDMA can also produce rapid tolerance is unknown. A
low dose of MDMA followed by a neurotoxic dose
within minutes or hours would, in all likelihood, pro-
duce a potentiated hyperthermic reaction much as is
observed following the administration of low dose
MDMA in binge protocols where the rectal temperature
increases following each subsequent dose separated by 3
h [37]. This would result in increased neurotoxicity [38].
Separation of the low and high dose MDMA by 96 h
resulted in no change in the hyperthermic response of
neurotoxic MDMA and a similar lack of effect was
observed with a 24 h interval [21]. This allows us to
rule out changes in the hyperthermic reaction as a fac-
tor involved in the neuroprotection observed as pre-
viously described [20,21].
At doses that produce neurotoxicity, MDMA produces
a neuroinflammatory reaction characterised by an
increase in IL-1b levels and microglial activation in the
frontal cortex [9,10,32,33,39]. A single low dose of
MDMA given 96 h earlier reduces the elevation in IL-
1b levels induced by neurotoxic MDMA. Although the
participation of IL-1b in MDMA-induced neurotoxicity
has not been thoroughly established, it appears it may
play at least a partial role in its development since com-
pounds which reduce IL-1b release and microglial acti-
vation following MDMA partially protect against 5-HT
neurotoxicity [32,39].
The suppression of the increase in IL-1b levels follow-
ing neurotoxic MDMA is accompanied by an increase
in IL-1ra levels in the frontal cortex, an effect not
observed following neurotoxic MDMA given alone [33;
present results]. This increase in IL-1ra levels is due to
the pretreatment with low dose MDMA rather than to
an interaction between the two treatments since the
increase is also observed 96 h after the pretreatment.
IL-1ra, the endogenous antagonist of IL-1b,w h i c hm a y
be released as a consequence of large increases in IL-1b
levels, binds to the IL-1RI with high affinity and inhibits
IL-1b signal transduction thus providing a mechanism
for limiting IL-1b mediated responses [40]. In fact, IL-
1ra has been shown to protect in several models of
brain injury including ischemic, excitotoxic and trau-
matic brain insults [41-44]. The role of this antagonist
in protection is further supported by studies in which
inhibition or deletion of endogenous IL-1ra enhances
Figure 5 Effect of pretreatment with IL-1b on MDMA (12.5 mg/
kg, i.p.)-induced neurotoxicity in frontal cortex 7 days later. IL-
1b (2.5 pg, intracortical) given 96 h before neurotoxic MDMA
prevented the loss of 5-HT transporters in the ipsilateral (A) but not
in the contralateral (B) frontal cortex. Results shown as mean ± s.e.
mean, n = 4-7. Different from saline-treated controls: *P < 0.05, **P
< 0.01. Different from neurotoxic MDMA:
ΔP < 0.05. One-way
ANOVA followed by Newman-Keuls test.
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responses [46]. In addition, endogenous IL-1ra has been
implicated in the neuroprotective effects of cannabinoids
[47] and we have demonstrated that a CB2 agonist pro-
vides partial protection against the neurotoxic effects of
MDMA [32]. Thus, this increase in IL-1ra levels follow-
ing neurotoxic MDMA in pretreated animals may con-
tribute to the tolerance observed. In fact it is thought
that the relative production of IL-1ra or IL-1b in
response to either mild or severe ischemia appears to be
quite important in determining outcome [48].
Although IL-1ra may be involved in the expression of
tolerance since low dose MDMA pretreatment increases
its levels following challenge with neurotoxic MDMA, it
is not clear that it is the triggering factor since levels of
the antagonist are unaltered at early time points increas-
ing only 96 h after the dose of MDMA. Furthermore, it
is not increased 24 h after low dose MDMA, a protocol
that also provided neuroprotection.
Low dose MDMA did, however, increase IL-1b levels
at an early time point (3 h) and produce changes in the
expression of the IL-1 type I receptor. The IL-1R has
high affinity for both IL-1b and its antagonist, IL-1ra.
Following the action of various proteases, the receptor is
cleaved from the membrane and released into the extra-
cellular space. At early time points (3 h and 6 h after
low dose MDMA administration) there is an increase in
the expression of the receptor in the soluble fraction.
The expression normalises at 24 h and increases again
at 96 h. Expression of the receptor in the membrane
fraction was unaltered at all time points, thus the overall
increase may possibly indicate synthesis of the receptor.
The expression of the receptor in the soluble fraction
represents levels of the proteolytic cleaved extracellular
domains of the membrane-bound receptor. This
released or soluble form of the receptor, sIL-1RI, binds
IL-1b but mediates no signal transduction [25]. Thus,
sIL-1RI acts a soluble-decoy receptor for IL-1b, inhibit-
ing the actions of IL-1b at the membrane bound form
of IL-1RI. Alongside IL-1ra it attenuates the effects of
IL-1b and potentially protects against the deleterious
effects of excessive release of the cytokine [49]. Thus,
t h ei n c r e a s ei nt h es o l u b l ef o r mo ft h er e c e p t o r9 6h
after low dose MDMA in conjunction with the increase
in levels of the antagonist may lead to a reduction in
the consequences of the elevation of IL-1b levels
induced by neurotoxic MDMA. However, similar to IL-
1ra, the possible role of this receptor in the tolerance
observed is not clear since expression of the soluble
form of the receptor is not increased 24 h after low
dose MDMA, time at which neuroprotection is
observed.
In order to explore the role of IL-1b as a trigger of
preconditioning, sIL-1RI was given with the
preconditioning dose of MDMA, 96 h before neurotoxic
MDMA. This treatment attenuated the protective effect
of the low dose MDMA in the ipsilateral side of the
frontal cortex having no effect in the contralateral side.
Although the soluble receptor also has affinity for IL-1ra
[49], the increase in IL-1b levels in the frontal cortex
following low dose MDMA and the lack of modification
of IL-1ra levels at the same early time points may shift
the balance of binding towards the cytokine and away
from the antagonist. Therefore, these results suggest a
role for IL-1b in the development of tolerance and are
supported by studies which describe an important role
for NF-B in ischemic tolerance [50].
Interestingly, the administration of IL-1b directly into
the cortex mimicked the preconditioning effect of low
dose MDMA. The infusion of the cytokine in the frontal
cortex 96 h before neurotoxic MDMA prevented the
loss of 5-HT transporter observed after the drug, pro-
viding further support for a role of IL-1b in the develop-
ment of delayed tolerance. Similar preconditioning
effects have been observed in other models of damage.
Thus, administration of the cytokine directly into the
brain induced ischemic tolerance in gerbils [51].
Conclusions
Low dose MDMA produces delayed preconditioning in
rats. The tolerance against neurotoxic MDMA-induced
5-HT transporter loss involves IL-1b. Additional studies
are required to identify the role of mediators further
downstream in IL-1b induced tolerance against MDMA-
induced neurotoxicity.
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